verview:
Ang et al identified prognostic groups for patients with oropharyngeal squamous cell carcinoma. This can help to identify patients who may benefit from more aggressive or a novel therapy. The authors are from multiple universities in the United States.
Patient selection: oropharyngeal squamous cell carcinoma, T2 to T4
Parameters:
(1) HPV status of the tumor
(2) number of pack years smoling
(3) T stage
(4) N stage
|
HPV |
Pack Years |
T Stage |
N Stage |
Risk Group |
|
positive |
<= 10 |
NA |
NA |
low |
|
positive |
> 10 |
NA |
N0 to N2a |
low |
|
positive |
> 10 |
NA |
N2b or N3 |
intermediate |
|
negative |
<= 10 |
T2 or T3 |
NA |
intermediate |
|
negative |
<= 10 |
T4 |
NA |
high |
|
negative |
> 10 |
NA |
NA |
high |
|
Risk Group |
4-Year Survival |
|
low |
83% |
|
intermediate |
56% |
|
high |
38% |
Specialty: Hematology Oncology, Surgery, general, Otolaryngology
